Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line Treatment for Patients with BRAF V600E-mutated mCRC By Ogkologos - June 25, 2025 394 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Addressing Cancer Pain with Complementary Methods (Part 2) April 10, 2023 Coronavirus y COVID-19: Qué deben saber las personas con cáncer June 24, 2020 Targeted Therapy for Treating Advanced Gastrointestinal Stromal Tumors (GISTs): The ASCO... January 24, 2022 For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment September 23, 2019 Load more HOT NEWS Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens... 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily... Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity...
